GUARDANT HEALTH, INC. (GH): what the price requires
At today's price, GUARDANT HEALTH, INC. (GH) is priced for today's economics sustained for ~20.8 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-19 · Source: https://boothcheck.com/report/GH
Headline
| Field | Value |
|---|---|
| Ticker | GH |
| Company | GUARDANT HEALTH, INC. |
| Current price | $158.60/sh |
| Composition | Oncology 70% / Biopharma & data 21% / Screening 8% / Licensing and other 1% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | revenue-multiple |
| EV / sales paid | 20.8x |
| Steady-state operating margin assumed | 25.8% |
| Must persist for | 20.8y |
The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.
Solve inputs: computed at a 12.2% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.9 years.
Reconcile: at the x-ray's 9.3% required return this reads ~13.4 years; the models below use their own rates.
How unusual the bet is: elevated (limited comparison data)
| Reference | Value |
|---|---|
| sustained it ~10 years at this level | 14% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | — | 0 | — |
| Earnings | — | 0 | — |
| Relative | 4.82x | 2 | expensive |
| Growth | 3.60x | 2 | expensive |
Families that call it expensive: Relative, Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.6%); the inversion above states its own rate.
Per-Model Detail (n=4)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $0.00 | — | no | Negative/zero FCF — equity value floored at $0 |
| DCF Exit Multiple | Growth | $0.00 | — | no | Negative/zero FCF or EBITDA — equity value floored at $0 |
| Relative Valuation | Relative | $32.92 | 4.82x | yes | P/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | — | — | no | — |
| Two-Stage Excess Return | Asset | — | — | no | — |
| Discounted Future Market Cap | Growth | $143.28 | 1.11x | yes | Rev $1.1B, growth 30% (input: historical growth; tapered), Terminal P/S: 9.6x / 12.0x / 14.4x (bear / base = today's held flat / bull, cap 12x) |
| Peter Lynch Fair Value | Relative | $0.00 | — | no | Negative/zero EPS — earnings-based value floored at $0 |
| Margin Trajectory | Growth | $26.02 | 6.10x | yes | Margin ramp: -40% → 12% over 7yr, rev growth 30% (input: historical growth; tapered) |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | — | — | no | — |
| EV/EBITDA Relative | Relative | — | — | no | — |
| FCF Yield | Earnings | — | — | no | — |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | — | — | no | — |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $32.92 | 4.82x | yes | Revenue $1.08B × sector P/S 4.0x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | — | — | no | — |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $400.7m |
| Interest coverage | -107.7x |
| Share count CAGR (dilution) | 6.5% |
| Burning cash | yes |
Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.
Bullet Takeaways
Guardant does not yet earn an operating profit, so the market prices it on sales: about 18 times revenue. That multiple implies the business eventually reaches a roughly 26% operating margin and grows revenue near its self-funding ceiling for close to 19 years.
The business is scaling fast. Q1 2026 revenue rose 48% to $301.7 million, and the Shield colorectal screening line jumped from $5.7 million to $41.6 million as test volume and reimbursement improved. The growth is real; the question is the multiple paid for it.
The risk is cash. The company is still burning, with trailing operating income near negative $448 million and a net debt position. The price assumes nearly two decades of ceiling-rate growth and a margin the company has never earned. The moat must prove durable before the math works.
Bull Case
The structural advantage that defines Guardant Health is being first and proprietary in blood-based cancer testing, and the margin and volume data are starting to show it converting into a real business. Guardant runs liquid biopsy, detecting cancer from a blood draw rather than tissue, across oncology (70% of revenue), biopharma and data (21%), and the newer screening line (8%). The moat is the testing platform and the clinical data behind it. The FY2025 10-K describes the technical edge directly: the Guardant Reveal test "has been migrated to the Smart Platform which could maximize detection sensitivity without requiring tissue" (FY2025 10-K, accession 0001576280-26-000013), and the company's research targets detecting colorectal cancer signals "in the bloodstream, including DNA that is shed by tumors" (accession 0001576280-26-000013). A non-invasive test that works from blood is a genuine switching-cost and convenience advantage over tissue-based incumbents.
The operating leverage is finally appearing in the numbers. Q1 2026 revenue grew 48% year over year to $301.7 million, with oncology at $205.0 million, biopharma and data at $53.0 million, and screening at $41.6 million. Non-GAAP gross margin reached 66%. The standout was Shield, the colorectal screening test: revenue climbed from $5.7 million a year earlier to $41.6 million as test volume hit 44,000, and screening gross margin jumped from 18% to 56% as cost per test fell to $420 and average selling price rose after a Medicare fee update. That is the shape of a business crossing from science project to scalable product, where each incremental test gets cheaper and more profitable.
Management is leaning into the inflection. The company raised full-year 2026 revenue guidance to $1.30 to $1.32 billion, implying 32% to 34% growth, and now expects screening revenue of $186 to $198 million on 230,000 to 245,000 Shield tests. It also guided to a smaller free-cash-flow burn than 2025, the first sign the spending curve is bending. Against the diagnostics peer set of Natera, Veracyte, and RadNet, Guardant is the name with both a fast-growing core oncology franchise and a screening option that could become the larger business if Shield scales the way the trajectory suggests. The price assumes that outcome; the recent results are the first installments of evidence that it can happen.
Bear Case
The bear case is structural and sits on the balance sheet: Guardant is still burning cash, and the price assumes it grows into a profitability it has never demonstrated. Trailing operating income is around negative $448 million, the company carries a net debt position of roughly $401 million, and it is funding a commercial expansion, particularly for Shield, out of that thinning cushion. A business that loses money at scale is fragile in a specific way: it depends on continued access to capital, on reimbursement decisions it does not control, and on the assumption that today's burn buys tomorrow's profit. If the capital markets tighten or the screening ramp stalls, the runway shortens fast, and a company priced for two decades of growth has no margin for a funding interruption.
The valuation makes the fragility worse, not better. At about 18 times revenue, the price implies the business eventually earns a roughly 26% operating margin, an enormous swing from the current deeply negative margin, and sustains revenue growth near its self-funding ceiling for close to 19 years. History says only about 14% of comparable fast-growers sustain that pace for even ten years. No valuation family reaches the price: the relative-multiple lens lands near $33, the margin-trajectory lens near $26, and even the discounted-future-market-cap frame, the most generous, only just reaches the quote. When the entire valuation rests on a future margin the company has not earned and a growth duration almost no company achieves, the price is a forecast stacked on a forecast.
The third risk is competitive and scientific. The screening opportunity that carries the bull case is also the most contested, and Guardant's own filing acknowledges the technical difficulty: its research "to date indicate that somatic signatures alone may be insufficient" for the sensitivity colorectal screening demands (accession 0001576280-26-000013). Shield is competing against established stool-based and emerging blood-based screens, and adoption depends on guideline inclusion, payer coverage, and physician behavior, none of which move on the company's timeline. Oncology, the profitable-at-gross-margin core, faces Natera and others pushing on the same minimal-residual-disease and therapy-selection markets. A 48% revenue quarter is impressive, but it is being celebrated by a market that has already priced 19 years of it. The bet is not whether Guardant has good technology. It is whether good technology plus heavy losses plus intense competition can compound into a 26% margin business before the cash and the patience run out.
Valuation
Guardant is valued on sales rather than profit, because it does not yet earn a normal operating margin. At $131.80 (June 27, 2026) the market is paying about 18 times revenue, which inverted at a 12% cost of capital implies the business eventually reaches an operating margin near 26% and grows revenue at its self-funding ceiling for roughly 19 years. Each percentage point of assumed growth moves that implied horizon by about 2.7 years. The priced-in assumption reads as elevated: only about 14% of comparable fast-growers have sustained that pace for even a decade, and the required margin is a destination the company has never reached.
The model X-ray is thin precisely because the company is unprofitable, so the asset-based and earnings-power families have no applicable methods. What remains says the price is rich. The relative-multiple lens (relative valuation and P/sales sector) lands near $33, about a quarter of the price. The margin-trajectory model lands near $26. Only the discounted-future-market-cap frame, which projects revenue forward and applies a terminal multiple, reaches near the quote at about $143. With just two families populated and both flagging the price as expensive, the read is that the valuation is carried almost entirely by one generous forward method.
The balance sheet is the constraint that turns an aggressive valuation into a genuine risk. Guardant is still burning, trailing operating income near negative $448 million, with net debt of about $401 million, and it is spending to scale Shield. The encouraging signal is direction: Q1 revenue up 48%, screening gross margin up to 56%, and guidance for a smaller cash burn than 2025. Those are real and material to the forward thesis. But they do not change the core arithmetic. The reasonable conclusion is that Guardant is a fast-growing, technically differentiated diagnostics company whose price already assumes it becomes a large, high-margin business over nearly two decades. The growth is buying the story credibility; the price has already paid for the ending.
Catalysts
The Q1 2026 report on May 8 was the most recent catalyst and a clear positive. Revenue rose 48% to $301.7 million, led by oncology at $205.0 million, with screening at $41.6 million and biopharma and data at $53.0 million. Non-GAAP gross margin improved to 66%. The company raised full-year 2026 revenue guidance to $1.30 to $1.32 billion, implying 32% to 34% growth. (Sources: StockTitan 8-K and earnings release; The Motley Fool Q1 2026 transcript; Yahoo Finance.)
Shield is the catalyst that matters most. Screening revenue jumped from $5.7 million a year earlier to $41.6 million as Shield reached 44,000 tests, screening gross margin rose from 18% to 56%, cost per test fell to $420, and average selling price improved after a Medicare fee update. Full-year screening guidance is now $186 to $198 million on 230,000 to 245,000 Shield tests, with full-year free-cash-flow burn guided to $185 to $195 million, better than 2025. The signals to watch are Shield test volume and average selling price, guideline and payer coverage decisions, and the pace at which the cash burn narrows. Because the price assumes nearly two decades of ceiling-rate growth and a margin not yet earned, each quarter is a referendum on whether the screening ramp and the path to profitability are real. (Sources: StockTitan earnings release; The Motley Fool transcript; AOL Q1 2026 transcript.)
Peer Cohorts (Per Segment, With Filing Citations)
Guardant Health (single operating segment) (reported)
- NTRA (NATERA, INC.)
- FY2025 10-K: …issued a final judgment at this time. The Company plans to appeal the final judgment to the Ninth Circuit Court of Appeals. In February 2025, Guardant filed suit against the Company and two of its former employees who recently joined the Company in the United States District Court for the Northern District of…
- FY2025 10-K: Recent Sales of Unregistered Securities None. Purchases of Equity Securities by the Issuer and Affiliated Parties None. ITEM 6. [Reserved.] 72 Table of Contents ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and…
- VCYT (VERACYTE, INC.)
- FY2025 10-K: …resources and assessing financial performance. The Company has a single reporting unit associated with the development and commercialization of diagnostic tests and biopharmaceutical services. The accounting policies of the Company's single segment are the same as those described in the summary of significant…
- FY2025 10-K: …are recorded within impairment of assets on the consolidated statement of operations. The Company assessed the impairment of the intangible assets using an income approach which involved significant unobservable inputs, which are Level III inputs, including revenue projections and cash flow projections. This method…
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.